A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation
Journal of the American Academy of Dermatology
Clinical Summary
View sourceWhat was studied
A retrospective claims analysis evaluated trends in the costs of biologic agents used for psoriasis, comparing price growth with medical inflation.
Key findings
The cost of most psoriasis biologics increased faster than medical inflation.
Clinical implications
Expect prices of most psoriasis biologics to outpace medical inflation; discuss affordability and coverage with patients and account for budget impact in treatment planning.
Related Questions
Explore related topics and deepen your understanding